# A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

> **NCT03139487** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 176 (estimated)

## Conditions studied

- Cancer-associated Thrombosis
- Esophageal Cancer
- Stomach Cancer
- Hepatocellular Carcinoma
- Pancreatic Cancer
- Duodenal Cancer
- Esophagogastric Junction Cancer
- Malignant Gastrointestinal Stromal Tumor
- Ampulla of Vater Cancer
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Dalteparin
- **DRUG:** apixaban

## Key facts

- **NCT ID:** NCT03139487
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-07
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2020-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139487, "A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03139487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*